

May 18, 2022
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Chimerix announces sale of brincidofovir to Emergent BioSolutions

TOKYO, Japan, May 17, 2022 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio" or "the Company") today announced that Chimerix, Inc. (Headquarters: Durham, North Carolina, "Chimerix") announced in a press release dated May 16, 2022 (EST) that Chimerix has entered into a definitive agreement with Emergent BioSolutions Inc. (Headquarters: Gaithersburg, Maryland, "Emergent") to acquire Chimerix's exclusive worldwide rights for the antiviral drug brincidofovir ("BCV").

Please refer to Chimerix website for details of the press release.

<https://ir.chimerix.com/press-releases>

Symbio's exclusive worldwide license to develop, manufacture, and commercialize BCV from Chimerix in September 2019 for all indications except the prevention and treatment of orthopox infections will be assigned from Chimerix to Emergent but will not be affected otherwise by the aforementioned acquisition. The Company is currently conducting global clinical trials of BCV injection for adenovirus (AdV) infection after hematopoietic stem cell transplantation and preparing for global clinical trials for BK virus infection after renal transplantation. In addition, the Company is aiming to expand the market and maximize the business value of BCV and initiated a joint study with Brown University in the U.S. in March 2022 to investigate the anti-tumor effect of BCV on cytomegalovirus-associated glioblastoma (GBM).

The Company does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 2022.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About Anti-viral Drug Brincidofovir

Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved and marketed in the United States and the European Union, but unapproved in Japan. As BCV exhibits not only higher anti-viral activity, but also a superior safety profile in comparison with CDV, BCV is expected to be an effective treatment against a wide spectrum of dsDNA viruses such as herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV) and BK virus, papillomavirus. Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent that can reduce the risk of nephrotoxicity, which is a serious side effect of CDV. Symbio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants Symbio exclusive worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of orthopox infections (which includes smallpox and monkeypox).

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma. For further information, please visit the Chimerix website, www.chimerix.com

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. (NYSE: EBS) is a pharmaceutical company based in Gaithersburg, Maryland, USA. Through its pipeline of innovative vaccines and therapeutics, Emergent develops, manufactures, and distributes products worldwide to protect against public health threats. For more information, visit Emergent website at <https://www.emergentbiosolutions.com>.

About Symbio Pharmaceuticals Limited

Symbio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., Symbio Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.